Literature DB >> 498418

Distribution and metabolism of rubidazone and daunorubicin in mice.

R Baurain, D Deprez-De Campeneere, A Trouet.   

Abstract

A comparative investigation of the distribution and metabolism of rubidazone and daunorubicin was conducted in NMRI mice, after a single IV dose of either rubidazone (8.4 mg/kg) or daunorubicin (7 mg/kg). The anthracyclines were analyzed by high-pressure liquid chromatography and fluorometry. Daunorubicin was the main compound found after daunorubicin administration, except in kidney and urine, where daunorubicinol was the main metabolite with trace amounts of aglycone. In contrast, rubidazone undergoes extensive metabolism into daunorubicin, daunorubicinol, and aglycone. The total drug level is significantly lower after rubidazone administration in kidney, heart, gastrointestinal tract, spleen, and urine, and the biliary excretion of rubidazone is more important than that of daunorubicin. When compared with daunorubicin, significantly less daunorubicinol is produced after rubidazone administration.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 498418     DOI: 10.1007/bf00253103

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  Adriamycin-a review.

Authors:  S K Carter
Journal:  J Natl Cancer Inst       Date:  1975-12       Impact factor: 13.506

Review 2.  Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin.

Authors:  T Skovsgaard; N I Nissen
Journal:  Dan Med Bull       Date:  1975-02

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  A phase 1 and 2 trial of rubidazone in patients with acute leukemia.

Authors:  R S Benjamin; M J Keating; K B McCredie; G P Bodey; E J Freireich
Journal:  Cancer Res       Date:  1977-12       Impact factor: 12.701

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

6.  [Study of the experimental anti-tumor action of a new semi-synthetic antibiotic: rubidazone (22 050 R. P.)].

Authors:  R Maral; G Ponsinet; G Jollès
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1972-07-10

7.  Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127), and their derivatives in rats.

Authors:  G Zbinden; E Brändle
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

8.  Biological activities of rubidazone.

Authors:  R Maral
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

9.  Clinical study of rubidazone (22 050 R.P.), a new daunorubicin-derived compound, in 170 patients with acute leukemias and other malignancies.

Authors:  C Jacquillat; M Weil; M F Gemon-Auclerc; V Izrael; A Bussel; M Boiron; J Bernard
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

10.  Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.

Authors:  D S Alberts; T Van Daalen Wetters
Journal:  Br J Cancer       Date:  1976-07       Impact factor: 7.640

  10 in total
  4 in total

1.  Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chromatography: plasma levels in DBA2 mice.

Authors:  R Baurain; D Deprez-De Campeneere; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice.

Authors:  D Deprez-de Campeneere; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

3.  Daunorubicin-DNA and doxorubicin-DNA. A review of experimental and clinical data.

Authors:  A Trouet; D Deprez-De Campeneere
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 4.  Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.

Authors:  J Bouma; J H Beijnen; A Bult; W J Underberg
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.